Atopic Dermatitis Drugs Market– Statistics And Analysis & Forecast To 2030Posted by Mrudula Karmarkar on January 10th, 2023 The global atopic dermatitis drugs market size is expected to reach USD 27.68 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.0% from 2022 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance. A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD. Support from regulatory authorities, such as the provision of fast-track designation, is anticipated to impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.’s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market. An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor. The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy. The COVID-19 pandemic has increased the frequency of handwashing, leading to cracked and dry skin prone to infections among atopic dermatitis patients. Incidence of hand eczema is also on the rise owing to constant exposure to oil-stripping soaps and handwash. This is an unmet need, thereby creating an opportunity for market players to develop moisturizer-based creams and ointments to capture the newly formed segment. To Request Sample Copy of this report, click the link: https://www.grandviewresearch.com/industry-analysis/atopic-dermatitis-drugs-market/request/rs1 Growing prevalence of atopic dermatitis, strong pipeline, emergence of biologics, and untapped opportunities are anticipated to drive the market over the forecast period. The prevalence of atopic dermatitis is rising steadily. As per Acta Derm Venereologica Journal in 2020, the prevalence of atopic dermatitis diagnosed by the doctor ranged between 17.1% in Europe and 10.2% in Asian adults, while the rates were 22.6% and 0.96%, respectively, in children. It has a substantial financial and social burden and has been categorized as the largest skin disability. Atopic Dermatitis Drugs Market Report Highlights
Atopic dermatitis is a lucrative market and companies are investing in R&D to develop novel products to capture the market. The growing number of drugs entering the late phase of clinical trials by demonstrating positive results is expected to aid revenue growth for major companies in the coming years. For instance, in April 2021, Galderma announced phase 2b results for its under development drug Nemolizumab, in patients suffering from uncontrolled atopic dermatitis. In March 2021, Pfizer stated that under development abrocitinib was non-inferior to the existing treatment Dupixent by Sanofi. Furthermore, there is an unmet need for oral drugs among atopic dermatitis patients, which can be fulfilled by the launch of abrocitinib, which is a Janus kinase 1 (JAK1) inhibitor. Cara Therapeutics’ Korsuva is a phase 2 oral drug for pruritus caused due to atopic dermatitis. Furthermore, rising product approvals and the emergence of biologics for the management of atopic dermatitis are anticipated to boost market growth during the forecast period. For instance, in June 2022, Sanofi announced U.S. FDA approval of Dupixent (dupilumab) for children between 6 months to 5 of age with atopic dermatitis. In January 2022, AbbVie Inc. announced the U.S. FDA approval of RINVOQ (upadacitinib) for the management of severe atopic dermatitis in children over 12 years of age and adults. RINVOQ is suggested to patients who don’t respond to their previous treatment with injections and pills. Biologics is a relatively new class of treatment in the market. The targeted approach of the biologics segment is a crucial factor facilitating the growth of this segment. The high rate of disease recurrence is driving companies to invest in the development of novel biologics with high efficacy. Although biologics are not considered first-line treatment, dermatologists believe that for people who face an issue with atopic dermatitis for a major portion of a year, biologics should be considered as the first choice owing to their high efficacy, safety, and targeted approach in treating the disease. List of Key Players in Atopic Dermatitis Drugs Market
Like it? Share it! More by this author |